T he US Food and Drug Administration (FDA) has expanded the indication for Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo to include adults aged 18–59 years who have chronic ...

T he FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus ...

The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy ...

Abrysvo triggers your immune response to make a type of protein (antibodies) against the respiratory syncytial virus. ... In the U.S., you can report side effects to the FDA at ...

References: US Food and Drug Administration. FDA requires Guillain-Barré syndrome (GBS) warning in the prescribing information for RSV vaccines Abrysvo and Arexvy.

US FDA approves Abrysvo, Pfizer’s vaccine for the prevention of respiratory syncytial virus (RSV) in older adults. Pfizer Inc. News release. May 31, 2023. Accessed October 23, 2024.

Zinger Key Points. Pfizer's Abrysvo is FDA-approved to prevent RSV in adults 18-59 at high risk. Abrysvo remains the only RSV vaccine approved for pregnant individuals to protect infants.

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk for disease.

The Food and Drug Administration (FDA) has approved Abrysvo ® (respiratory syncytial virus [RSV] vaccine) for active immunization for the prevention of lower respiratory tract disease (LRTD ...

The FDA thumbs up for Abrysvo comes on top of its original approval in May of 2023 for those 60 and older. Three months later, the U.S. regulator also endorsed Abrysvo for women in weeks 32 ...

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus ...

Findings from this self-controlled case series showed an increased risk of GBS during the 42 days following vaccination with Abrysvo (9 excess cases per million doses; incidence rate ratio [GBS ...